ACMG-Based Reclassification of TP53 Variants in Oncogenetic Practice
Documenta Haematologica - Revista Romana de Hematologie · 23.06.2026 · 4 (2) · 43-48
DOI: 10.59854/dhrrh.2026.4.2.43 ↗Kurz gefasst
Fachartikel in der Zeitschrift Documenta Haematologica - Revista Romana de Hematologie, online erschienen am 23.06.2026. Verfasst von Elena BULANCEA und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Variants of uncertain significance (VUS) in cancer predisposition genes, such as TP53, represent a major challenge in clinical interpretation. The p53 protein functions as a tumor suppressor involved in cell cycle regulation, apoptosis, and DNA repair mechanisms. Loss-of-function variants may contribute to the development of various cancer types or to the Li-Fraumeni syndrome. The DNA-binding domain (DBD) is essential for p53 function, and variants occurring within this region may have significant functional impact. Materials and Methods: TP53 variants located within the DNA-binding domain and classified as VUS were extracted from the ClinVar database. A total of 93 variants met the inclusion criteria and were re-evaluated according to ACMG/AMP guidelines and available literature data. Bioinformatic tools, including gnomAD and MutationTaster, were used to support the reclassification process.
Results
Among the 93 VUS variants analysed, 6 variants (6.45%) retained their VUS status, whereas 87 variants (93.55%) were reclassified as Likely Pathogenic, supporting the clinical relevance of their localization within a key functional domain. Although six variants initially reached a cumulative score of 5 points, partly due to their absence from large population databases such as gnomAD, the available evidence was insufficient to justify a change toward a benign classification.
Conclusions
Reclassification of TP53 variants within the DNA-binding domain highlights the importance of periodic re-evaluation of VUS. The integration of functional, bioinformatic, and clinical data, together with expert genetic assessment, is essential for accurate diagnostic interpretation and appropriate clinical management.
Zitieren
APA
BULANCEA, E., IORDACHE, S., JARDAN, C., & CALUGARU, O. (2026). ACMG-Based Reclassification of TP53 Variants in Oncogenetic Practice. Documenta Haematologica - Revista Romana de Hematologie, 4(2), 43-48. https://doi.org/10.59854/dhrrh.2026.4.2.43
Vancouver
BULANCEA E, IORDACHE S, JARDAN C, CALUGARU O. ACMG-Based Reclassification of TP53 Variants in Oncogenetic Practice. Documenta Haematologica - Revista Romana de Hematologie. 2026;4(2):43-48. doi:10.59854/dhrrh.2026.4.2.43
BibTeX
@article{BULANCEA2026,
author = {BULANCEA, Elena and IORDACHE, Stefania and JARDAN, Cerasela and CALUGARU, Onda-Tabita},
title = {ACMG-Based Reclassification of TP53 Variants in Oncogenetic Practice},
journal = {Documenta Haematologica - Revista Romana de Hematologie},
year = {2026},
volume = {4},
number = {2},
pages = {43--48},
doi = {10.59854/dhrrh.2026.4.2.43}
}
EUVIMED